Company / Cash & Equivalents
Travere Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$93.0M
FY2025
5-year range
$58.2M / $165.8M
FY2021-FY2025
Trend
+58.9%
vs FY2024
Sector context
#144 of 207
Health Care
What the data says
At $93M, Travere Therapeutics, Inc.'s cash & equivalents ranks #144 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $18M in FY2016 to $166M in FY2021.
Based on SEC 10-K filings.
$93M in FY2025 with a 5-year CAGR of +1.9%.
Improved from $58M to $93M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +14.7%
- 5-Year CAGR
- +1.9%
- 10-Year CAGR
- -
Sector benchmark
#144 of 207 in Health CareTop 70% of 207This company $93.0M Sector average $669.5M
▼
-86.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 58.9% year-over-year.
- Ranks #144 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $93.0M | +58.9% |
| FY2024 | $58.5M | +0.6% |
| FY2023 | $58.2M | -5.7% |
| FY2022 | $61.7M | -62.8% |
| FY2021 | $165.8M | +95.5% |
| FY2020 | $84.8M | +35.8% |
| FY2019 | $62.4M | -39.3% |
| FY2018 | $102.9M | +172.1% |
| FY2017 | $37.8M | +107.7% |
| FY2016 | $18.2M | -51.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026